IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) has announced that its Compensation Committee granted non-qualified stock options to a newly hired employee on December 26, 2024. The grant includes options to purchase 31,400 shares of common stock at an exercise price of $25.86 per share, matching the closing price on Nasdaq Global Select Market on the grant date.
The options were granted under the company's 2023 Employment Inducement Incentive Award Plan and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years. The options have a 10-year term and are subject to continued employment.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato che il suo Comitato per la Compensazione ha concesso opzioni su azioni non qualificate a un nuovo dipendente il 26 dicembre 2024. La concessione include opzioni per acquistare 31.400 azioni ordinarie a un prezzo di esercizio di $25.86 per azione, corrispondente al prezzo di chiusura sul Nasdaq Global Select Market alla data della concessione.
Le opzioni sono state concesse nell'ambito del Piano di Incentivazione alla Assunzione 2023 dell'azienda e matureranno nel corso di quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei tre anni successivi. Le opzioni hanno una durata di 10 anni e sono soggette a continua occupazione.
IDEAYA Biosciences (NASDAQ: IDYA) ha anunciado que su Comité de Compensación otorgó opciones de acciones no calificadas a un nuevo empleado el 26 de diciembre de 2024. La concesión incluye opciones para comprar 31,400 acciones comunes a un precio de ejercicio de $25.86 por acción, igualando el precio de cierre en el Nasdaq Global Select Market en la fecha de concesión.
Las opciones se otorgaron bajo el Plan de Incentivos por Contratación 2023 de la empresa y se adquirirán en un período de cuatro años, con el 25% adquiriéndose después del primer año y el 75% restante adquiriéndose mensualmente durante los tres años siguientes. Las opciones tienen un plazo de 10 años y están sujetas a empleo continuo.
IDEAYA Biosciences (NASDAQ: IDYA)는 2024년 12월 26일 새로 채용된 직원에게 비자격 주식 옵션을 부여했다고 발표했습니다. 이 부여는 행사 가격이 $25.86인 31,400주의 일반 주식 구매 옵션을 포함하며, 부여일 Nasdaq Global Select Market의 종가와 일치합니다.
옵션은 회사의 2023년 고용 유도 인센티브 보상 계획에 따라 부여되었으며, 4년에 걸쳐 발생합니다. 첫 해에 25%가 발생하고, 나머지 75%는 이후 3년 동안 월별로 발생합니다. 옵션의 유효 기간은 10년이며, 지속적인 고용 조건이 있습니다.
IDEAYA Biosciences (NASDAQ: IDYA) a annoncé que son Comité de Rémunération a accordé des options d'achat d'actions non qualifiées à un nouvel employé le 26 décembre 2024. La concession comprend des options pour acheter 31 400 actions ordinaires à un prix d'exercice de $25.86 par action, correspondant au prix de clôture sur le Nasdaq Global Select Market à la date de la concession.
Les options ont été accordées dans le cadre du Plan d'Incentives à l'Embauche 2023 de l'entreprise et seront acquises sur une période de quatre ans, avec 25 % qui seront acquis après la première année et les 75 % restants qui seront acquis mensuellement au cours des trois années suivantes. Les options ont une durée de 10 ans et sont soumises à un emploi continu.
IDEAYA Biosciences (NASDAQ: IDYA) hat bekanntgegeben, dass das Vergütungskomitee am 26. Dezember 2024 nicht qualifizierte Aktienoptionen an einen neu eingestellten Mitarbeiter vergeben hat. Die Zuteilung umfasst Optionen zum Kauf von 31.400 Stammaktien zu einem Ausübungspreis von $25.86 pro Aktie, der dem Schlusskurs an der Nasdaq Global Select Market am Tag der Zuteilung entspricht.
Die Optionen wurden im Rahmen des 2023 Employment Inducement Incentive Award Plans des Unternehmens vergeben und werden über einen Zeitraum von vier Jahren fällig, wobei 25% nach dem ersten Jahr und die verbleibenden 75% monatlich über die folgenden drei Jahre fällig werden. Die Optionen haben eine Laufzeit von 10 Jahren und sind an eine Fortführung des Arbeitsverhältnisses gebunden.
- None.
- None.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302339483.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What is the exercise price of IDYA's newly granted stock options on December 26, 2024?
How many shares are covered by IDYA's December 2024 inducement stock option grant?
What is the vesting schedule for IDYA's December 2024 inducement stock options?
What is the term length of IDYA's December 2024 inducement stock options?
